H5N1 Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)
Condition:   Influenza A Virus, H5N1 SubtypeInterventions:   Biological: Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant;   Biological: Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvantSponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Emory UniversityActive, not recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2013 Category: Research Source Type: clinical trials

Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
Condition:   InfluenzaIntervention:   Biological: GSK1557484A vaccineSponsor:   GlaxoSmithKlineActive, not recruiting - verified July 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2013 Category: Research Source Type: clinical trials

PaxVax Announces Positive Results for Oral Ad4 Vaccine Technology
Phase One Study of Oral Replicating Vaccine for H5N1 Published in Lancet Infectious Diseases MENLO PARK, Calif.--(BUSINESS WIRE)--Jan 31, 2013 - PaxVax, Inc., which develops and commercializes innovative vaccines against infectious diseases in a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 31, 2013 Category: Pharmaceuticals Source Type: clinical trials

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
Condition:   Pandemic H5N1 InfluenzaIntervention:   Biological: Adjuvanted H5N1 pandemic influenza vaccineSponsors:   Novartis Vaccines;   Department of Health and Human ServicesCompleted - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 20, 2013 Category: Research Source Type: clinical trials

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
Condition:   Pandemic H5N1 InfluenzaIntervention:   Biological: Adjuvanted H5N1 pandemic influenza vaccineSponsors:   Novartis Vaccines;   Department of Health and Human ServicesCompleted - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 20, 2013 Category: Research Source Type: clinical trials